Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by ecanadian2on Nov 25, 2021 11:54pm
80 Views
Post# 34167503

RE:FACTS OVER OPINIONS

RE:FACTS OVER OPINIONSJust to be clear these are all opinons or at most educated(?) guesses: under-valued? drive-up share price? no further financing?

My opinions are that:
the only thing that will drive up and support the share price are tangible positive developments (on the bio research/trials front) and that funding will be required in not too distant future - 12 months?
Are they much better off that they were 6 months ago - absolutely!

Of course in terms of share price short/mid-term ... anything can happen - just look at 27 million plus trading days on Nov 3 and 4 - more than double all outstanding shares.


Anyway I will have find that mute button for spacelab etc - he/she is quite a disgruntled person, very ignorant and delusional. 
<< Previous
Bullboard Posts
Next >>